Ariel Perez
Overview
Explore the profile of Ariel Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez A, Al Sagheer T, Nahas G, Linhares Y
Front Immunol
. 2024 May;
15:1412002.
PMID: 38779668
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for hematological malignancies, showing high efficacy in patients with relapsed or refractory (R/R) disease and otherwise poor prognosis in...
2.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bucklein V, Volkl S, et al.
Sci Adv
. 2023 Sep;
9(38):eadg3919.
PMID: 37738350
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how (CAR) T cell expansion...
3.
Bucklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al.
Hemasphere
. 2023 Jul;
7(8):e907.
PMID: 37449196
Real-world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient- and disease-related...
4.
Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier C, et al.
Blood Adv
. 2022 Jul;
6(13):3970-3973.
PMID: 35816359
No abstract available.
5.
Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35580927
Background: CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity...
6.
Perez A, Jester G, Galili Y, El-Far A, Baidas S
J Med Cases
. 2021 Aug;
11(7):215-220.
PMID: 34434398
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by a reciprocal translocation between the long arms of chromosomes 9 and 22 that results in expression of the oncoprotein BCR-ABL1....
7.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al.
Blood
. 2021 Jun;
138(24):2499-2513.
PMID: 34166502
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell-related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers...
8.
Cortes-Bullich A, Perez A, Bachmeier C, Mhaskar R, Chavez J, Shah B, et al.
Transplant Cell Ther
. 2021 Jun;
27(9):768.e1-768.e6.
PMID: 34077811
CD19-directed chimeric antigen receptor (CAR) T cell therapy with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) is approved for the standard of care treatment of relapsed or refractory large B cell...
9.
Sarwari N, Galili Y, Perez A, Avgeropoulos N, Tseng J
J Thorac Oncol
. 2019 Jul;
14(8):e179-e180.
PMID: 31345344
No abstract available.
10.
Mejia M, Perez A, Watson H, Sanchez D, Parellada J, Madruga M, et al.
Case Reports Immunol
. 2018 Oct;
2018:9093623.
PMID: 30302295
Type B lactic acidosis is a rare metabolic complication sometimes associated with hematologic malignancies. When present, this type of lactic acidosis is most commonly seen in patients with high-grade lymphomas...